Featured Publications
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management
Daniele S, Kim S, Grada A, Moore A, Suozzi K, Bunick C. Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management. American Journal Of Clinical Dermatology 2022, 24: 199-223. PMID: 36539678, DOI: 10.1007/s40257-022-00746-4.Peer-Reviewed Original ResearchConceptsTruncal acne vulgarisAcne vulgarisTruncal acneHalf of patientsFacial acne vulgarisSignificant psychosocial burdenAvailable treatment optionsCommon skin disorderTreatment guidelinesPsychosocial burdenTreatment optionsTruncal involvementPatient managementFacial lesionsClinical problemSkin disordersUpper armCosmetic approachSebaceous glandsCurrent MedicalSkin areasPatientsAcneFocused reviewFurther investigationRandom skin biopsies for diagnosis of intravascular large B-cell lymphoma: Retrospective analysis of 31 biopsies from a US dermatology inpatient consultative service with literature review
Kim SR, Ko CJ, Nelson CA, Ramachandran S, Gehlhausen JR. Random skin biopsies for diagnosis of intravascular large B-cell lymphoma: Retrospective analysis of 31 biopsies from a US dermatology inpatient consultative service with literature review. Journal Of The American Academy Of Dermatology 2022, 88: 714-716. PMID: 36152693, DOI: 10.1016/j.jaad.2022.09.016.Peer-Reviewed Original ResearchClustered intraepidermal lymphocytes and Langerhans cell microgranulomas are consistently observed in hyperkeratotic palmoplantar eczema compared with palmoplantar psoriasis and mycosis fungoides palmaris et plantaris
Kim SR, McNiff JM, Ko CJ. Clustered intraepidermal lymphocytes and Langerhans cell microgranulomas are consistently observed in hyperkeratotic palmoplantar eczema compared with palmoplantar psoriasis and mycosis fungoides palmaris et plantaris. Journal Of The American Academy Of Dermatology 2021, 87: 884-886. PMID: 34883152, DOI: 10.1016/j.jaad.2021.11.057.Peer-Reviewed Original ResearchIL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
Ortolan LS, Kim S, Crotts S, Liu LY, Craiglow BG, Wambier C, Paschoal RS, King BA, Jabbari A. IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. Journal Of Allergy And Clinical Immunology 2019, 144: 1731-1734.e1. PMID: 31470035, PMCID: PMC6900443, DOI: 10.1016/j.jaci.2019.08.014.Peer-Reviewed Original ResearchRapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy
Kim R, Heaton H, Liu LY, King BA. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy. JAMA Dermatology 2018, 154: 370-371. PMID: 29387870, DOI: 10.1001/jamadermatol.2017.5778.Peer-Reviewed Original Research
2020
Structural properties of target binding by profilaggrin A and B domains and other S100 fused-type calcium-binding proteins
Hinbest AJ, Kim SR, Eldirany SA, Lomakin IB, Watson J, Ho M, Bunick CG. Structural properties of target binding by profilaggrin A and B domains and other S100 fused-type calcium-binding proteins. Journal Of Dermatological Science 2020, 100: 39-49. PMID: 32893105, PMCID: PMC7752840, DOI: 10.1016/j.jdermsci.2020.08.009.Peer-Reviewed Original ResearchAmino Acid SequenceAnnexin A2Binding SitesCrystallography, X-RayFilaggrin ProteinsHumansHydrophobic and Hydrophilic InteractionsIntermediate Filament ProteinsIntermediate FilamentsKeratinocytesKeratinsMolecular Docking SimulationMutationProtein BindingProtein Conformation, alpha-HelicalProtein DomainsProtein PrecursorsRecombinant ProteinsS100 ProteinsScreening Novel Agent Combinations to Expedite CTCL Therapeutic Development
Mirza FN, Yumeen S, Lewis JM, King ALO, Kim S, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. Journal Of Investigative Dermatology 2020, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.Peer-Reviewed Original ResearchJAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaJAK inhibitionCTCL cellsMalignant cutaneous T-cell lymphomasAdvanced cutaneous T-cell lymphomaTreatment of CTCLAvailable systemic treatment optionsSkin-homing T lymphocytesSystemic treatment optionsT-cell lymphomaCTCL cell linesHistone deacetylase inhibitionGeneralized cytotoxic effectExpression of Bcl2Advanced diseaseSuch patientsPeripheral bloodTreatment optionsJAK/STAT pathwayT lymphocytesPreclinical assessmentTherapeutic targetStrong potentiationExtrinsic apoptosis pathwayDeacetylase inhibition
2019
Segmental neurofibromatosis 1 with gonosomal mosaicism
Kim R, Kibbi N, Imaeda S. Segmental neurofibromatosis 1 with gonosomal mosaicism. International Journal Of Dermatology 2019, 58: e255-e256. PMID: 31286507, DOI: 10.1111/ijd.14586.Peer-Reviewed Case Reports and Technical Notes